Finch Therapeutics Group Stock Market Value
| FNCH Stock | USD 13.50 0.06 0.45% |
| Symbol | Finch |
Finch Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Finch Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Finch Therapeutics.
| 09/18/2025 |
| 12/17/2025 |
If you would invest 0.00 in Finch Therapeutics on September 18, 2025 and sell it all today you would earn a total of 0.00 from holding Finch Therapeutics Group or generate 0.0% return on investment in Finch Therapeutics over 90 days. Finch Therapeutics is related to or competes with Celyad Oncology, Starpharma Holdings, Charlottes Web, and Positron Corp. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally admin... More
Finch Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Finch Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Finch Therapeutics Group upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.9 | |||
| Information Ratio | 0.0319 | |||
| Maximum Drawdown | 15.53 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 3.41 |
Finch Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Finch Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Finch Therapeutics' standard deviation. In reality, there are many statistical measures that can use Finch Therapeutics historical prices to predict the future Finch Therapeutics' volatility.| Risk Adjusted Performance | 0.0523 | |||
| Jensen Alpha | 0.1237 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0379 | |||
| Treynor Ratio | 0.6874 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Finch Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Finch Therapeutics Backtested Returns
Finch Therapeutics is not too volatile at the moment. Finch Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0808, which denotes the company had a 0.0808 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Finch Therapeutics Group, which you can use to evaluate the volatility of the firm. Please confirm Finch Therapeutics' Coefficient Of Variation of 1542.94, mean deviation of 1.32, and Downside Deviation of 1.9 to check if the risk estimate we provide is consistent with the expected return of 0.19%. Finch Therapeutics has a performance score of 6 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.2, which means not very significant fluctuations relative to the market. As returns on the market increase, Finch Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Finch Therapeutics is expected to be smaller as well. Finch Therapeutics right now shows a risk of 2.3%. Please confirm Finch Therapeutics total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Finch Therapeutics will be following its price patterns.
Auto-correlation | -0.01 |
Very weak reverse predictability
Finch Therapeutics Group has very weak reverse predictability. Overlapping area represents the amount of predictability between Finch Therapeutics time series from 18th of September 2025 to 2nd of November 2025 and 2nd of November 2025 to 17th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Finch Therapeutics price movement. The serial correlation of -0.01 indicates that just 1.0% of current Finch Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.01 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Finch Therapeutics lagged returns against current returns
Autocorrelation, which is Finch Therapeutics pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Finch Therapeutics' pink sheet expected returns. We can calculate the autocorrelation of Finch Therapeutics returns to help us make a trade decision. For example, suppose you find that Finch Therapeutics has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Finch Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Finch Therapeutics pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Finch Therapeutics pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Finch Therapeutics pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Finch Therapeutics Lagged Returns
When evaluating Finch Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Finch Therapeutics pink sheet have on its future price. Finch Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Finch Therapeutics autocorrelation shows the relationship between Finch Therapeutics pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Finch Therapeutics Group.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Finch Pink Sheet
Finch Therapeutics financial ratios help investors to determine whether Finch Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Finch with respect to the benefits of owning Finch Therapeutics security.